IIRC from FTM's tables (or an article, I can't remember right now), they were not sicker. Ours are 90% Stage iV, 10% Stage III. I'm pretty sure the other trials actually had healthier patients. I'll double check when I have time.
It doesn't matter, the only valid comparison is with the control arm of this trial. In any case, you can't get much sicker than >90% in stage 4. If patients in all those other trials were sicker then you would expect the MOS for their control arms to be much less than 5.4 months, not greater.
Market Data 
Markets 
AI
